ClinicalTrials.gg
CompletedNCT05393076Updated Jan 18, 2023

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

A Phase 1 interventional study of Linerixibat in Pruritus, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pruritus by GlaxoSmithKline — 1 open to participants now, 1 under way, 1 of them phase 3. Pruritus · GlaxoSmithKline.

Enrollment
11th of 11
8 · median 52
Started
2022
with 1 other
Phase 1
4 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Pruritus by GlaxoSmithKline, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 1, and was the 9th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

1 of the 12 studies in Pruritus by GlaxoSmithKline is open now. Recruiting first, the newest first:

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pruritus by GlaxoSmithKline, or all of them as a file.
02

Study summary

This is a phase 1, open-label, single-dose study in adults with moderate hepatic impairment (defined as Child-Pugh B cirrhosis) and matched healthy control participants with normal hepatic function. All participants in both cohorts (moderate hepatic impairment and matched healthy controls) will receive a single dose of the study drug, linerixibat. The purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) and safety of linerixibat.

03

Conditions studied

  • Pruritus

Keywords

  • Linerixibat
  • Pruritus
  • GSK2330672
  • Pharmacokinetics
  • Primary biliary cholangitis
  • Hepatic impairment
  • Liver Cirrhosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  • Age: 18 to 75 years of age (inclusive).
  • Weight greater than (>) 45 kilograms (kg) and (BMI) 18.5 - 40 kg per square meter (kg/m\^2) (inclusive).
  • Male and female- A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies; not a woman of (WOCBP) or a WOCBP who agrees to follow guidance during the treatment period and until at least 4 weeks after the last dose of study treatment.
  • Participant capable of giving signed .

Participants with Moderate Hepatic Impairment (Cohort 1):

  • Moderate hepatic impairment (of any etiology) and clinically stable for at least 1 month prior to screening.
  • score of 7-9.
  • Previous confirmation of liver cirrhosis confirmed by either- Liver , Imaging technique, or Noninvasive liver assessment consistent with cirrhosis.
  • Hepatic impairment needs to be chronic (>6 months), stable.

Matched Healthy Control Participants (Cohort 2):

  • Participants will be matched by age plus or minus (±)10 years to a corresponding participant in the hepatic impairment group. Age should remain between 18 and 75 years of age (inclusive).
  • Participants will be matched by total body weight ±15 percentage (%) to a corresponding participant in the hepatic impairment group.
  • Participants will be matched by gender and race to a corresponding participant in the hepatic impairment group.
  • Healthy participant as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and .

Exclusion criteria

Exclusion Criteria:

All Participants:

  • Participants are excluded from the study if any of the following medical conditions apply:
  • History of cholecystectomy, current symptomatic cholelithiasis or inflammatory gallbladder disease.
  • Significant history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Any abnormality identified at the screening medical assessment (physical examination/medical history review), clinical laboratory tests, or 12-lead .
  • Current clinically significant diarrhea.
  • History of gastrointestinal surgery with ileal resection or ileal bypass at any time.
  • Any within the past 5 years except for basal cell or squamous cell carcinoma of the skin disease for 3 years.
  • Participants with unstable cardiac function or participants with uncontrolled hypertension.
  • Any current medical or psychiatric condition, clinical or laboratory abnormality, or examination finding which may affect study compliance or procedures or possible consequences of the study.
  • Administration of any other Ileal bile acid transport (IBAT) inhibitor (including linerixibat) in the 3 months prior to screening.
  • For healthy participants, past or intended use of over the counter or prescription medication, including vitamins and dietary or herbal supplements) within 7 days prior to the first dose of study medication.
  • Current enrolment in a clinical trial or recent participation in a clinical trial and has received an investigational product within the following time-period prior to study drug administration in the current study: 30 days.
  • Positive pregnancy test at screening or at Day -1 in women of .
  • Positive (HIV) antibody test.
  • Healthy control participant has corrected interval using the Fridericia's correction formula (QTcF) >450 millisecond (msec); or participant with hepatic impairment has a baseline QTcF >480 msec on ECG.
  • Regular use of known drugs of abuse or history of drug abuse or dependence within 6 months of the study.
  • Moderate (or greater) alcohol consumption defined as one standard drink per day for women and two drinks per day for men.
  • History of regular use of tobacco or nicotine-containing products.
  • Positive drug/alcohol screen at Screening or at Day -1.
  • Where participation in the study would result in donation of blood or blood products more than 500 milliliter (mL) within a 56-day period.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that contraindicates participation in the study.

Participants with Hepatic Impairment (Cohort 1):

  • History of gastric or oesophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated medically or endoscopically.
  • Grade 3 ascites (large ascites with marked abdominal distension) to medical therapy.
  • Refractory hepatic encephalopathy as judged by the investigator.
  • score of 10 or higher or Child-Pugh score of 6 or lower.
  • Hepatopulmonary or hepatorenal syndrome and history of liver transplantation.
  • Evidence of active infection, including spontaneous bacterial peritonitis.
  • Confirmed hepatocellular carcinoma (HCC) or biliary cancer.
  • Alanine amino transferase () value >3 x (ULN).
  • count less than (\<) 50,000/microliter (μl).

Matched Healthy control participants (Cohort 2):

  • Current or chronic history of liver disease or known hepatic or biliary abnormalities and/or confirmed hepatocellular carcinoma or biliary cancer.
  • Screening ALT or aspartate aminotransferase (AST) above the upper limit of normal (ULN).
  • Elevated above the ULN unless this is due to underlying Gilbert's syndrome.
  • Presence of surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
  • Positive antibody ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Moderate hepatic impairment participants)

    Eligible participants to receive single dose of linerixibat.

    Drug: Linerixibat

  • Experimental
    Cohort 2 (Matched healthy control participants)

    Eligible participants to receive single dose of linerixibat

    Drug: Linerixibat

Interventions

  • Linerixibat dose and administration as per study intervention.

06

What researchers measure

Primary outcomes

  1. Plasma area under the concentration-time curve from time zero (pre-dose) to the time of the last quantifiable concentration [AUC(0-t)] following a single dose of linerixibat

    Time frame: Up to Day 3

  2. Maximum observed concentration (Cmax) following a single dose of linerixibat

    Time frame: Up to Day 3

Secondary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    AEs and SAEs will be collected

    Time frame: Up to Day 14

  2. Number of participants with clinically significant change from baseline in electrocardiogram (ECG)

    Time frame: Baseline (Day -1) and up to Day 3

  3. Number of participants with clinically significant change from baseline in vital signs

    Time frame: Baseline (Day -1) and up to Day 3

  4. Number of participants with clinically significant change from baseline in clinical laboratory tests

    Blood samples will be collected for the assessment of clinical laboratory tests

    Time frame: Baseline (Day -1) and up to Day 3

  5. Plasma area under the concentration-time curve from time zero (pre-dose) to 24 hours [AUC (0- 24)] following a single dose of linerixibat

    Time frame: Up to Day 3

  6. Apparent terminal phase half-life (t1/2) of linerixibat

    Time frame: Up to Day 3

  7. Apparent clearance (CL/F) of linerixibat

    Time frame: Up to Day 3

  8. Time to Cmax (tmax) of linerixibat

    Time frame: Up to Day 3

  9. Apparent terminal phase volume of distribution (Vz/F) of linerixibat

    Time frame: Up to Day 3

07

Study locations

2 sites
  • GSK Investigational Site
    Orlando, Florida 32809, United States
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Dec 2022, 4 months.

Of 21 phase 1 interventional studies under Pruritus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 26, 2022
StartActual
Jul 19, 2022
Primary completionActual
Dec 6, 2022
CompletionActual
Dec 6, 2022
Last update
Jan 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05393076
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 26, 2022
Start date
Jul 19, 2022
Primary completion
Dec 6, 2022
Completion
Dec 6, 2022
Last update
Jan 18, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linerixibat

Start the discussion